Cynapsedx
WebSummary Overview Number of Founded Organizations 1 CB Rank (Person) 672,540 Gender Male Christopher Stanley is the co-founder of CynapseDx. Jobs Number of Current Jobs 1 Christopher Stanley is the Co-Founder & CTO at CynapseDx. CynapseDx Co-Founder & CTO Recent News and Activity There is no recent news or activity for this profile. WebCynapseDx (formerly CellCap Technologies) is a company that develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from neurodegenerative diseases. It develops assays that can measure the oligomeric and aggregated forms of ß-amyloid, α-synuclein, and phospho-tau in blood. …
Cynapsedx
Did you know?
http://cynapsedx.com/news WebCynapseDx Limited Liverpool Science Park 131 Mount Pleasant Liverpool L3 5TF; 0151 705 3400; [email protected]
WebCynapseDx (formerly CellCap Technologies) is a company that develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from neurodegenerative diseases. View company Need Data? Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via … WebJun 8, 2024 · CynapseDx develops products to isolate proteins or cells from whole blood. Its primary focus is neurodegenerative diseases, such as Parkinson’s or Alzheimer’s Disease.
Webcynapsedx.com Claim your profile to get in front of buyers, investors, and analysts. Submit Your Analyst Briefing Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Learn more. Overview & Products Financials People Alternatives & Competitors Customers CynapseDx has not claimed their Profile. WebCynapseDx develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from a neurodegenerative disease, such as …
WebGemelli Biotech's main competitors include Vivid Genomics, ALCEDIAG, Quadrant Biosciences and CynapseDx. Compare Gemelli Biotech to its competitors by revenue, employee growth and other metrics at Craft. Advanced Product Craft Intelligence Portal Craft API Supplier Intelligence Platform Company Search (Free) Solutions Craft for …
WebCynapseDx is currently conducting a trial to demonstrate that our assays can save money and resources for any health service by cost effectively identifying patients mis … bin2coeWebJul 1, 2024 · March 26th 2024. PharmaKure is delighted to announce the completion of the acquisition of the CynapseDx assays for oligomeric proteins. This is the final step that secured invesment of £4 million from a private investor and the UK Future Fund to finance clinical trials on their leading drug candidate PK051 for Alzheimer's disease. 26 March 2024 bin2coffWebJul 12, 2012 · CynapseDx's latest funding round was a Seed VC for $0.11M on July 12, 2012. View all funding This profile has not been claimed. You're more than your latest … bin 2 barrel waste 2 fuel bvWebCynapseDx has been developing products to isolate proteins or cells from whole blood since 2012. At the heart of our techniques is an antibody coated large ultra-dense magnetic particle that can force its way through the viscous, cell-rich media of blood to encou nter and bind proteins. These can be free in plasma, or cell-associated. cypher armzWebCynapseDx Connect to CRM Summary Financials People Technology Signals & News Similar Companies Highlights Employee Profiles 2 About CynapseDx has 2 current employee profiles, including Co-Founder & CTO Christopher Stanley. Contacts We're working on getting contact data for CynapseDx Find more contact data in Search! Get … bin2cleanWebCynapseDx has been developing products to isolate proteins or cells from whole blood since 2012. At the heart of our techniques is an antibody coated large ultra-dense … cypher arrayWebCynapseDx is currently conducting a trial to demonstrate that our assays can save money and resources for any health service by cost effectively identifying patients mis-diagnosed with Parkinson’s disease. This will secure the funding to complete the development of all 3 assays for ß-amyloid, α-synuclein and phospho-tau. ... cypher arms